Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Welcome Email

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics

EASD 2026 Winners/Not Winners Analysis: Who Came Out on Top… and Who Didn’t?

Here is a brief preview of this blast: Following EASD 2026 (Sep 28-Oct 2; Milan, Italy), FENIX has conducted a winners/not winners analysis, assessing which companies gained further momentum from the conference, remained static, or trended in the wrong direction. Spoiler alert: Lilly clearly came out on top, with EloraTZP setting a new efficacy benchmark for what may be achievable with an amylin + incretin combination. However, winning is not a zero-sum game...

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.